# US 2021/0277093 A1 · Immunotherapeutic compositions and methods of production for coronavirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277093 A1
- Document ID: US20210277093A1
- Status: Published application
- Kind: A1
- Application number: 17/196,846
- Filed: 2021-03-09
- Published: 2021-09-09
- Earliest claimed: 2020-03-09
- Assignees: Adma Biologics, Inc.
- Applicants: ADMA Biologics, Inc.
- Inventors: James Mond; Adam S. Grossman
- Web page: https://patentgrep.com/patent/US20210277093A1

## CPC

- G01N 33/56983: {Viruses}
- A61K 39/39525: {Purification}
- A61K 39/39575: {against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants}
- A61K 39/42: viral
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C07K 16/102: Coronaviridae (F)
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61K 2039/505: {comprising antibodies}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/21: from primates, e.g. man
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Embodiments of the present disclosure relate generally to compositions and methods for the treatment and/or prevention of pathogenic viral infections, e.g., coronavirus infections. In particular, the present disclosure provides human plasma compositions and immunoglobulin prepared therefrom containing select antibody titers specific for coronavirus (e.g., SARS CoV-2), methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions for prophylactic administration and/or therapeutic treatment (e.g., passive immunization or immune-prophylaxis).

## Claims

### Claim 1

A method of producing an immune globulin comprising:
1) obtaining a plurality of plasma samples from a plurality of plasma donors;
2) conducting a first assay on each plasma sample to measure total anti-SARS CoV-2 antibody titer;
3) selecting, based upon the first assay, plasma samples having a total anti-SARS CoV-2 antibody binding titer that is at least two-fold higher than the amount of total anti-SARS CoV-2 antibody binding titer in a control sample;
4) conducting a second assay on each selected plasma sample from step (3) to measure SARS CoV-2 neutralizing antibody titer;
5) identifying, based upon the second assay, plasma samples having a neutralizing antibody titer in the lower 65% of all plasma samples assayed and excluding the identified plasma samples from further processing;
6) pooling the non-excluded plasma samples from step (5); and
7) preparing immune globulin from the pooled plasma samples of step (6).

### Claim 2 (depends on 1)

The method of claim 1, wherein each of the plurality of plasma donors is a COVID-19 convalescent plasma donor.

### Claim 3 (depends on 1)

The method of claim 1, wherein each of the plurality of plasma donors is a COVID-19 vaccinated plasma donor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the control sample is a mixture of plasma samples obtained from 100 or more random human plasma donors.

### Claim 5 (depends on 1)

The method of claim 1, wherein the control sample is a commercially available immune globulin.

### Claim 6 (depends on 1)

The method of claim 1, wherein step (5) comprises identifying, based upon the second assay, plasma samples having a neutralizing antibody titer in the lower 70% of all plasma samples assayed and excluding the identified plasma samples from further processing.

### Claim 7 (depends on 1)

The method of claim 1, wherein step (5) comprises identifying, based upon the second assay, plasma samples having a neutralizing antibody titer in the lower 75% of all plasma samples assayed and excluding the identified plasma samples from further processing.

### Claim 8 (depends on 1)

The method of claim 1, wherein the number of non-excluded, pooled plasma samples is 250 or more.

### Claim 9 (depends on 1)

The method of claim 1, wherein the number of non-excluded, pooled plasma samples is 500 or more.

### Claim 10 (depends on 1)

The method of claim 1, wherein the immune globulin is prepared using a cold alcohol fractionation process that isolates the immune globulin fraction from the pooled plasma as a solution.

### Claim 11 (depends on 1)

The method of claim 1, wherein the immune globulin is combined with a pharmaceutically acceptable carrier.

### Claim 12

A method of providing immunotherapy to a subject in need thereof, comprising administering to the subject an immunotherapeutic composition comprising:
A) an immune globulin prepared from pooled plasma samples, wherein the pooled plasma samples are obtained by:
1) obtaining a plurality of plasma samples from a plurality of plasma donors;
2) conducting a first assay on each plasma sample to measure total anti-SARS CoV-2 antibody titer;
3) selecting, based upon the first assay, plasma samples having a total anti-SARS CoV-2 antibody binding titer that is at least two-fold higher than the amount of total anti-SARS CoV-2 antibody binding titer in a control sample, wherein the control sample is a mixture of plasma samples obtained from 100 or more random human plasma donors;
4) conducting a second assay on each selected plasma sample from step (3) to measure SARS CoV-2 neutralizing antibody titer;
5) identifying, based upon the second assay, plasma samples having a neutralizing antibody titer in the lower 65% of all plasma samples assayed and excluding the identified plasma samples from further processing; and
6) pooling the non-excluded plasma samples from step (5) to generate the pooled plasma samples; and
B) a pharmaceutically acceptable carrier;
wherein the immunotherapeutic composition is administered to the subject so as to provide from about 1.5-2.0 grams of immune globulin per kilogram of the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein each of the plurality of plasma donors is a COVID-19 convalescent plasma donor.

### Claim 14 (depends on 12)

The method of claim 12, wherein each of the plurality of plasma donors is a COVID-19 vaccinated plasma donor.

### Claim 15 (depends on 12)

The method of claim 12, wherein the immunotherapeutic composition further comprises a biologically active agent selected from the group consisting of an anti-inflammatory agent, an anti-cancer agent, an anti-microbial agent, an antihistamine, a cytokine, and a chemokine.

### Claim 16 (depends on 12)

The method of claim 12, wherein the immunotherapeutic composition further comprises an immunotherapeutic agent selected from the group consisting of a recombinant antibody, an antibody fragment, an antibody-like molecule, a monoclonal antibody, an antiviral, an immunotherapeutic protein and an immunotherapeutic small molecule.

### Claim 17 (depends on 12)

The method of claim 12, wherein the immunotherapeutic composition further comprises an anti-inflammatory agent selected from the group consisting of a recombinant antibody, an antibody fragment, a monoclonal antibody, an anti-inflammatory protein and an anti-inflammatory small molecule.

### Claim 18 (depends on 12)

The method of claim 12, wherein the subject is diagnosed with COVID-19.

### Claim 19 (depends on 12)

The method of claim 12, wherein the subject is age 65 or older.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising an immune globulin obtained by the method of claim 1.
